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Blood–brain barriera b s t r a c t
Rabies is a lethal disease in humans and animals, killing approximately 60,000 people every year.
Currently, there is no treatment available, except post-exposure prophylaxis (PEP) that can be adminis-
tered whenever exposure to a rabid animal took place. Here we describe the beneficial effects of a com-
bination treatment initiated at day 4 post infection, containing anti-viral drugs and immune modulators
in infected mice. Combination therapy resulted in significant increase in survival time (P < 0.05) and
significantly lowers viral RNA in the brain and spinal cord (P < 0.05). Furthermore, treatment influenced
markers of pyroptosis and apoptosis and early inflammatory response as measured by the levels of
TNF-a. Morphological lesions were absent in rabies virus infected mice with few signs of inflammation.
However, these were not significant between the different groups.
 2018 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Rabies virus (RV) causes deadly encephalitis in animals and
humans, for which there is no treatment available to date. Once
neurological symptoms appear in exposed individuals, almost
100% of patients die. RV belongs to the family Rhabdoviridae and
is classified within the genus Lyssavirus. Disease is caused by any
of the known Lyssaviruses and it is believed that the mechanism
of pathogenesis does not differ between the different members of
this genus. There is a vaccine available against the prototype RV,
which is effective to prevent lethal infection and is the fore being
used in combination with hyperimmune serum as post-exposure
prophylaxis (PEP) [1]. The vaccine can be effective to a certain
extend against other lyssaviruses depending on the virus species
and the seed RV used for vaccine production [2]. Despite the avail-
ability of effective vaccines and the possibility to apply PEP in
exposed individuals, rabies still accounts for more than 60,000deaths annually, mainly among children and young adults in
resource-poor countries [3].
In developed countries where sporadic cases occur, patients will
be typically admitted to intensive care units, coma is induced and
often experimental treatment protocols are used, but so far with
limited success. The antivirals ribavirin and interferon-alpha
(IFN-a) administered intrathecally showed no effect on disease
course [4] whereas the benefit of antibodies given intrathecally is
not known [5] although it might be associated with brain hernia-
tion [6]. In a rabbit model of rabies, intrathecal administration of
an RV vaccine could increase survival of rabid animals [7]. To date,
only a few patients survived infection with RV, but although it is
not clear whether the applied interventions contributed to
survival, it is believed that the treatment allowed the patients to
mount a natural immune response to rabies, as evidenced by
development of neutralizing antibodies [8]. Although presence of
neutralizing antibodies in the rabies patients is not a guarantee
for survival, these observations led to the hypothesis that the
immune system could control and clear virus infection under
certain (yet to be defined) conditions. Despite the possible
involvement of the immune response in recovery from rabies, itred bat
2 B.E.E. Martina et al. / Vaccine xxx (2018) xxx–xxxis conceivable that infection with RV (or related lyssaviruses) trig-
gers an excessive, detrimental host response that needs to be con-
trolled in order for the infected individual to survive [9,10].
However, severe inflammation in human and animal fatal rabies
cases is usually not accompanied with extensive leukocyte infiltra-
tion in the brain and spinal cord [11]. Nevertheless, high levels of
cytokines and chemokines were demonstrated, in absence of
leukocyte infiltration, in transcriptomic studies of experimentally
infected mice [12]. Recent work in our lab has demonstrated acti-
vation of inflammatory responses and activation of the pyroptotic
cell death pathway by transcriptomic analysis during RV infection
[13]. Furthermore, based on our transcriptomic observations,
selected molecules that were upregulated during RV infections
were chosen as possible intervention strategies in the mouse
model. We have found that inhibitors of molecules such as caspase
1 (key pyroptotic molecule), MAP-kinases and TNF-a significantly
prolonged survival of mice infected with a lethal dose of RV either
given alone or in combination [14–16].
In this study we describe the effect of combination therapy that
targets viral replication and some pathways of the immune
response. We have compared the survival time, viral titers and
mRNA responses in experimentally infected mice and showed that
targeting both viral replication and part of the immune response
have a beneficial effect on the outcome of infection.2. Materials and methods
2.1. Viruses and drugs
The highly pathogenic silver-haired bat rabies virus (SHBRV-18,
a kind gift of Dr. B. Dietzhold, Jefferson University, USA) was used
in these studies. Viral stocks were generated on mouse neuroblas-
toma N2a cells and titers were determined by end-point titration
on BHK-21 cells and calculated using the Karber method as previ-
ously described [17].
A combination of six different compounds was used to formu-
late the treatment regimen (drugs; Table 1): caspase-1 inhibitor
(200 ng/mouse of Ac-YVAD-cmk from Sigma), TNF-a inhibitor
(0.1 mg per mouse of REMICADE from Janssen Pharmaceuticals),
MAP-kinase inhibitor (SORAFENIB tosylate 0.6 mg/mouse from
Bayer Health Care Pharmaceuticas), mouse IFN-a and b (6000 IU
each per mouse from PBL Assay Science), favipiravir (T705, 6 mg
per mouse from BOC Sciences), ribavirin (3.2 mg per mouse from
Tocris Bioscience) and human rabies immunoglobulins (HRIG 0.8
IU per mouse from NIBSC: WHO International Standard, The 2nd
International Standard). Mannitol was used as a blood-brain
barrier opener (0.5 ml of 25% mannitol from Sigma per mouse).
2.2. Infection experiment
Eight-week-old female C57BL/6 mice were infected via the
intramuscular route in the left hind leg with 106,13 TCID50 of virus
per mouse. All mice were weighted every day and scored for signs
of disease every two hours with the 4 h night break betweenTable 1
Overview of the experimental groups of mice that received infection and treatment.
Details of the viruses and the drugs used are described in the materials and methods
section.
Survival 50% mortality
Virus only (V) N = 9 N = 9
Virus + drugs + mannitol (V + D + M) N = 9 N = 9
Virus + drugs (V + D) N = 13 N = 13
Drugs + mannitol (D + M) N = 8 N = 8
Drugs only (D) N = 8 N = 8
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0: no signs. Score 1: ruffled hair and hunched back. Score 2: paral-
ysis of the inoculated leg, spasms. Score 3: paralysis in both hind
legs, severe spasms, circular movement, tail paralysis. Score 3 was
considered the humane end point of the experiment and mice were
euthanized by cervical dislocation when this score was reached.
2.3. Treatment with combination therapy
Two sets of experiments were conducted abbreviated as ‘‘sur-
vival” and ‘‘50% mortality”. An overview of the different treatment
groups is given in Table 1. Briefly, groups of 8-week-old female
C57BL/6 mice were inoculated intramuscularly in the left hind
leg with 106.3 TCID50/mouse of SHBRV-18. Four days after inocula-
tion, treatment was initiated with the combination of compounds
(described above) diluted mostly in DMSO (Sigma) or water was
injected intraperitoneally in 1 ml volume. Thirty minutes after
treatment with the combination of drugs mannitol was given
intraperitoneally in the respective groups (Table 1). For the sur-
vival experiments,. treatment with the combination of drugs was
given on days 4–12. Control groups included mice that were inoc-
ulated with virus, but did not receive any treatment or received the
treatment combination (with and without mannitol), but received
DMEM instead of virus (mock infection).
For the 50% mortality experiments, mice were inoculated with
virus (or DMEM) as described above and received the combination
treatment (with and without mannitol or no treatment) on days 4,
5, 6 and 7. Then all mice of these groups were euthanized in order
to compare the effect of treatment on a pre-determined time point
after infection (with mannitol: day 7; without mannitol: day 8).
2.4. Real time PCR
Brain samples were collected at the time of euthanasia from all
mice, weighted and stored at 80 C as 10% homogenate in DMEM
medium (Lonza, Basel, Switzerland) containing 10% penicillin and
streptomycin (Lonza). RNA was isolated using the MagNA Pure
LC 1.0 system and High Pure isolation kit (Roche, Mannheim, Ger-
many) according to the manufacturer’s procedures and quantified
using NanoDropTM ND-1000 UV–VIS Spectrophotometer (NanoDrop
Technologies, Wilmington DE, USA). Viral RNA was detected using
SHBRV-18 specific primers/probe combination as previously
described [19] with a modification of the SHBRV-18 probe and
the TaqManTM Fast Virus Master Mix (Applied Biosystems, Foster
City, CA, USA) (according to the instructions of the manufacturer
in a Applied Biosystems 7500 Fast Real-Time PCR System (Taq-
Man)). To measure expression level of several molecules involved
in the pyroptotic and apoptotic pathways, mRNA was transcribed
into cDNA using Oligo(dT)12–18 Primer (Invitrogen, Carlsbad CA,
USA) and Superscript III reverse transcriptase (Invitrogen) accord-
ing to the instructions of the manufacturer. The relative level of
transcripts was quantified using commercially available TaqMan
Gene Expression Assays of the respective genes (Applied Biosys-
tems, Foster City, CA, USA) and TaqMan Universal PCR Master
Mix (Applied Biosystems). Transcript numbers were expressed
relative to the housekeeping gene b–actin (Applied Biosystems)
following the formula 2-DCt⁄105 where DCt= Ctgene of interest –
Ctb–actin and were corrected for RNA quantity.
2.5. Histology and immunohistochemistry
For evaluation of microscopic abnormalities and for immuno-
histochemistry the right side of the mouse brain was placed in
10% neutral-buffered formalin. Brains were cut in six equal parts
in coronal plane, which were placed in two cassettes and then
embedded into paraffin wax. Paraffin blocks were cut innt prolongs survival of experimentally infected mice with silver-haired bat







































Fig. 1. Measurement of weight (A) and survival curves (B) of mice infected with
SHBRV-18, treated with combination therapy and followed for survival. Respective
virus and drug controls are also shown. In the weight curves the mean and standard
error of the mean are depicted. In the survival curves, mortalities were recorded per
B.E.E. Martina et al. / Vaccine xxx (2018) xxx–xxx 34-lm-thick serial sections and routinely stained with haema-
toxylin and eosin to detect light microscopic lesions. Immunohis-
tochemistry was performed to detect RV antigen and for the
detection of neuron specific antigen in specific cases. Briefly,
deparaffinised tissue sections were treated with 0.5% hydrogen
peroxide in 85% ethanol to quench endogenous peroxidase activity.
After antigen retrieval by incubation with 0.25% Trypsin, non-
specific binding was blocked using 20% normal goat serum diluted
in phosphate buffered saline (PBS). Slides were incubated with a
caprine polyclonal anti-rabies antibody (PA1201; FITC-
conjugated; SIFIN, Berlin, Germany; 1:500) at 4 C overnight.
Biotinylated goat-anti-FITC IgG (BA0601; Vector; 1:200) was used
as secondary antibody for 30 min at room temperature. Finally,
immunolabelling was visualized applying the avidin–biotin–perox
idase complex (ABC) method (PK6100; Vector Laboratories, Burlin-
game, CA, USA) with 3,3-diaminobenzidine-tetrahydrochloride
(DAB) as chromogen followed by slight counterstaining with
Mayer’s haematoxylin.
Evaluation of inflammatory cell infiltration and antigen label-
ling was performed using appropriate semi-quantitative scoring
systems from 0 to 3. Inflammation was scored on haematoxylin
and eosin (H&E) stained paraffin sections according to the number
of inflammatory cells in a 400x high power field (0: 0; 1: 1–5; 2: 6–
15; 3: >15). Analysis of immunohistochemically stained sections
was based on the number of cells positive for rabies virus antigen
in a 400x high power field (0: 0; 1: 1–7; 2: 8–15; 3: >15).
Telencephalon, hippocampus, di-/mesencephalon, cerebellum,
and medulla oblongata were evaluated separately and a mean
score was determined for each animal evaluated.12 h. Survival curves were compared with the Log-rank (Mantel-Cox) test.2.6. Statistical analyses
Body weight between the different groups was compared using
Bonferroni’s multiple comparison test (ANOVA). Survival curves
were compared with the Log-rank (Mantel-Cox) test. Viral and
mRNA levels were compared with the Mann-Whitney non-
parametric test. Inflammation and virus antigen in the brain of
infected animals was compared with the Kruskal-Wallis test. All
statistical analysis was performed using GraphPad software (Prism
5). Using bonferroni correction the p-value was adjusted for multi-







































Fig. 2. Viral RNA in the brain (b) and spinal cord (s.c) of treated mice (V + D + M and
V + D) compared to virus control groups (V). Mice that were followed for survival
are depicted here. Asterisks indicate significant differences (Mann-Whitney non-
parametric test).3. Results
3.1. Survival mice
We studied the effect of combination therapy on SHBRV-18
infected mice in two different experimental designs. First we stud-
ied the effect of the combination therapy on survival of experimen-
tally infected mice. Treatment of infected mice with the drug
combination led to weight loss (Fig. 1a), possibly as a result of
toxicity. Using ANOVA (Bonferroni’s multiple comparison test),
we demonstrated that the body-weight means in the V + D + M
group and V + D groups were significantly lower compared to the
virus control group (P = 0.04). The V + D + M group had the lowest
body weight means although not significantly lower than the V + D
group (P > 0.05). The control groups (V, D, D + M) did not show any
weight loss, suggesting that the treatment alone did not have a sig-
nificant effect on the body weight of the mice.
Nevertheless, treatment had a positive benefit on prolongation
of survival. Median survival time of the V + D + M group was pro-
longed with 36 h, whereas in the V + D group it was prolonged
with 48 h compared to virus control group (Fig. 1b). These differ-
ences were significant (p = 0.0156 and p = 0.0093 respectively).
To see whether the increased survival time correlated with amountPlease cite this article in press as: Martina BEE et al. Combination drug treatme
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untreated groups. V + D group of mice had significantly lower
RNA in the brain compared to V + D + M group (P = 0.001) and to
V group (P = 0.0004) (Fig. 2). In contrast, RNA in the spinal cord
was lowest in the V + D + M group compared to virus control (P
= 0.002). No difference was measured in the level of RNA in the
spinal cord of the V + D group compared to virus control (P > 0.05).
3.2. 50% mortality mice
In a second set of experiments we sought to investigate the
effect of treatment (with and without opening the blood-brain bar-
rier (BBB) and the blood-spinal cord barrier (BSCB)) measured on a
predetermined time point, by comparing virus titers, expression ofnt prolongs survival of experimentally infected mice with silver-haired bat
4 B.E.E. Martina et al. / Vaccine xxx (2018) xxx–xxxmRNA of several markers and inflammation in the brain. We
assumed that the best time point to compare the effect of treat-
ment was when 50% of the virus control mice had succumbed to
rabies infection. To this end, at 7 (with mannitol) and 8 (without
mannitol) days post infection (when 50% of the mice in the virus
control group had reached the humane end points and were euth-
anized) all remaining mice were euthanized irrespective of the
presence of clinical signs of disease.
First, we measured no significant weight loss in the 50% mortal-
ity groups. Next we compared viral RNA titers in the brain and
spinal cord of treated mice.
As shown in Fig. 3, viral RNA titers did not differ significantly in
the brains of treated mice (V + D + M or V + D) compared to virus
control. In contrast, the data suggest that viral RNA in the spinal
cord was significantly lower in the V + D + M group compared to
virus control (P < 0.0001) (Fig. 3). Furthermore, we investigated
the effect of the compounds that we used on host responses. Since
our combination treatment included inhibitors of pyroptosis and
inflammatory response, we measured the expression of the mRNA
of relevant markers of pyroptosis (CASP-1, IL-18, IL-1b, PYCARD),
apoptosis (CASP-3, CASP-8, cytochrome C and Bcl-2) and inflam-
mation (TNF-a) (Fig. 4). The data suggest that pyroptosis was
inhibited as evidenced by significantly lower mRNA transcripts
for CASP-1, IL-18 and PYCARD in the treated groups. However, this
was not the case in mice that also received mannitol. Similarly,




















































Fig. 3. Viral RNA in the brain (b) and spinal cord (s.c) of treated mice with (A) and
without (B) mannitol (V + D + M and V + D) compared to virus control groups (V).
50% mortality groups are depicted here. Asterisks indicate significant differences
(Mann-Whitney non-parametric test).
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inflammatory marker TNF-a was not affected by treatment.
The last parameter that we studied in these groups was inflam-
mation as evident in formalin-fixed brain tissues from the respec-
tive mouse groups. No pathological differences were seen in the
virus infected and treated mice compared to virus and treatment
controls (Fig. 5). However, few perivascular mononuclear inflam-
matory cells were seen in the virus-infected groups but not in
the treatment control groups (Supplementary Fig. 1). Nevertheless,
there was no significant difference in the extent of inflammation
between infected/treated mice and virus control mice. Rabies virus
antigen was detected in moderate to high numbers of neurons in
the brain of infected mice (Supplementary Fig. 1). Moreover, distri-
bution of viral antigen in the brain was similar between the groups
(Fig. 5).4. Discussion
We have shown that a combination of treatment including anti-
viral compounds and host-response modulators can increase sur-
vival time of rabies up to 48 h. This was observed in RV-infected
mice, when treatment was started four days after infection and
given for eight consecutive days. The treatment cocktails included
a selection of compounds with antiviral and immunomodulatory
effects. We have used IFN-a, IFN-b, ribavirin, and favipiravir as
antivirals. We and others have shown that all these compounds
can inhibit RV in vitro [18,20]. However, these compounds have
not proven effective in the clinic [4]. At the same time we wanted
to interfere with a part of the immune response, which has been
shown to be elevated in RV-infected mice [13]. Excessive immune
activation has also been associated with other neurodegenerative
diseases [21,22]. We have selected CASP-1, TNF-a, and MAP-
kinase as the immunomodulatory targets. First, we have recently
identified increased levels of CASP-1 in RV-infected mice and its
inhibition increased survival in infected mice [16]. CASP-1 is
involved in induction of an inflammatory form of programmed cell
death called pyroptosis [23] and its inhibition could provide neuro-
protection in mouse models of neurodegenerative diseases [24]. In
our study, the combination treatment excluding mannitol signifi-
cantly reduced CASP-1 mRNA expression (Table 2 and Fig. 4). This
observation suggests that inclusion of a CASP-1 inhibitor in the
treatment regimen may have a positive effect on the course of
rabies by reducing downstream excessive and possibly detrimental
pro-inflammatory responses after rabies infection. Second, TNF-ɑ
has been associated with severe rabies and inhibition of TNF sig-
naling, mitigate disease severity [25]. In addition, TNF-a has been
implicated in several neurodegenerative diseases, possibly due to
its neurotoxic activity [26] through elevated glutamate production
resulting in cell damage and death [27], its potential to damage the
mitochondria and induction of ROS production [28]. Third, MAPKs
regulate important cellular processes such as proliferation, stress
responses, apoptosis and immune defense [29]. MAPKs are also
involved in production of several cytokines, including TNF-a. Sor-
afenib is a MAPK inhibitor, which inhibits Ser/Thr kinases, which
was recently approved for the treatment of cancer. We postulated
that these molecules might be involved in induction of an aberrant
immune response responsible for rabies encephalitis. In addition,
studies published in this issue by Smreczak et al., have shown that
use of REMICADE or Sorafenib can increase survival time of rabies
infected mice [14]. Our hypothesis was that by opening the BBB
and BSCB we would increase the chances of compounds to reach
the infected sites of the brain and thereby inhibit virus replication
and/or a deleterious inflammatory response. However, we did not
see any significant benefit of using mannitol as a barrier opener in
the clinical course of rabies. Although viral titers were slightlynt prolongs survival of experimentally infected mice with silver-haired bat
Fig. 4. Expression of mRNA in the 50% mortality groups of mice. Solid symbols: virus infected and treated mice. Open symbols: mice received only treatment. Blue colors:
mice received combination therapy with mannitol. Green colors: mice received combination therapy without mannitol. Red color: virus control (no treatment). (For
interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
Table 2
Differential expression of mRNA for different markers in animals infected and treated with the different drug combinations as described in Table 1. Statistical differences are
written in bold. Mean mRNA values were compared with the non-parametric Mann-Whitney test.
CASP-1 IL-1b IL-18 PYCARD
V + D + M V + D + M V + D + M V + D + M
V 0.4994 0.6665 0.6048 0.0400
D + M 0.0196 1.000 1.000 0.3301
Bcl-2 Cyt c CASP-3 CASP-8 TNF-a
V + D + M V + D + M V + D + M V + D + M V + D + M
V 0.3401 1.000 0.0939 0.1135 0.3865
D + M 0.0196 0.0336 0.4140 0.2601 0.0056
CASP-1 IL-1b IL-18 PYCARD
V + D V + D V + D V + D
V <0.0001 0.9183 0.0002 0.0035
D 0.0125 0.0034 0.0027 0.4915
Bcl-2 Cyt c CASP-3 CASP-8 TNF-a
V + D V + D V + D V + D V + D
V 0.0513 0.0018 <0.0001 0.0012 0.5316
D 0.6904 0.5382 0.0002 0.6378 0.0003
B.E.E. Martina et al. / Vaccine xxx (2018) xxx–xxx 5lower in the spinal cord of mice that received mannitol compared
to the mice that did not, survival was prolonged in the mice that
were treated without mannitol. Our data suggest that mannitol
may not have facilitated the entrance of the compounds in the
brain in contrast to the spinal cord. It is possible that mannitol
may open the BSCB more efficiently than the BBB providing a pos-
sible explanation for our observations. It is known that the BSCB
shares the same principal building blocks with the BBB, but they
are morphological and functional different [30]. Furthermore,
regional permeability of the brain after disruption with mannitolPlease cite this article in press as: Martina BEE et al. Combination drug treatme
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also possible that the combination of compounds that we used
requires different levels of permeability (and subsequently effec-
tiveness) in the brain and spinal cord. It is also possible that
repeated administration of mannitol was too toxic for the mice.
Alternatively, the diuretic effect of mannitol may have resulted in
accelerated clearance of small molecules such as IFN-a, and
therefore no measurable antiviral effect.
As seen in Fig. 1a, the mean body weight of RV-infected mice


















































Fig. 5. Inflammation (A) and rabies virus antigen (B) in the brain from 50%
mortality groups. Shown are data from infected mice, which received combination
therapy with mannitol (7 days post infection) or combination therapy without
mannitol (8 days post infection), and from infected but untreated control mice (7
and 8 days post infection, respectively). No significant differences in the degree of
inflammation or amount of virus antigen were present between these 4 groups. No
inflammation and virus antigen was detected in the respective drug control groups
with and without mannitol.
6 B.E.E. Martina et al. / Vaccine xxx (2018) xxx–xxxsignificantly decreased over time compared to the (virus) controls,
which could indicate increased toxicity due to treatment. Toxicity
due to the treatment regimen (including mannitol) may have
counterbalanced the effects of treatment, masking the potential
of the combination therapy to treat rabies. On the other hand,
we cannot exclude the possible effect of mannitol itself. Mannitol
is an osmotic diuretic that may have influenced the weight as it
leads to dehydration.
The treatment also affected transcript levels of proteins
involved in pyroptosis and apoptosis, however this effect was not
seen in combination with mannitol. This loss of measurable effect
may also be explained by other mechanisms of action of mannitol.
For instance, it was shown that mannitol induces activation of
kinases and cell apoptosis [32]. We therefore cannot exclude that
mannitol may have had these effects in our study.
It is likely that survival as a read-out parameter was not sensi-
tive enough to measure the effect of treatment. Therefore, we
included a 50% mortality as a read-out parameter. The working
assumption was that since virus replication was not inhibited an
effect would be better evaluated before the system is overwhelmed
and the effect of treatment is reversed. Therefore we measured
several parameters in all groups when 50% of the mice in the con-
trol group died. We did not observe significant differences in the
50% mortality design. Since we used a highly pathogenic rabies
strain for these experiments with rapid development of clinical
signs in mice, it is possible that this time point was not the bestPlease cite this article in press as: Martina BEE et al. Combination drug treatme
rabies virus. Vaccine (2018), https://doi.org/10.1016/j.vaccine.2018.05.065choice. It is also possible that treating mice for longer periods of
time would be necessary to measure a significant effect; in this
experimental design, treatment was only given for three consecu-
tive days.
In conclusion, we have seen promising results with the
combination therapy that we have used here that warrant further
investigations. Future studies, including step-down approaches
(i.e. reduce the number of compounds in the combination) should
follow up in order to identify best combinations and further opti-
mize treatment strategies against rabies. In addition, more efforts
must be deployed in finding better BBB and BSCB openers to
enhance delivery of drugs in the brain and spinal cord.Ethical statement
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